Apimeds Pharmaceuticals US (APUS) Gains from Investment Securities (2023 - 2025)

Apimeds Pharmaceuticals US has reported Gains from Investment Securities for 3 years, with the latest figure at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Investment Securities rose 846.4% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2024 stood at $213692.0 (changed 0.0% YoY), and the FY2025 full-year result was $1.3 million, up 513.21% from the prior year.
• Gains from Investment Securities for Q4 2025 stood at $2.0 million, up from -$12859.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $2.0 million in Q4 2025, with the low at -$12859.0 in Q3 2025.
• Historically, Gains from Investment Securities has averaged $485476.8 across 3 years, with a median of $213692.0 in 2023.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities changed 0.0% — and 2025, when it soared 846.4%.
• Apimeds Pharmaceuticals US's Gains from Investment Securities stood at $213692.0 in 2023, then changed by 0.0% to $213692.0 in 2024, then soared by 846.4% to $2.0 million in 2025.
• The last three Gains from Investment Securities figures came in at $2.0 million (Q4 2025), -$12859.0 (Q3 2025), and -$9518.0 (Q2 2025), per Business Quant data.